The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease-Reference-Cited by-同舟云学术

The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease

Published:2017-05-24 Issue:3 Volume:31 Page:311-318
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Mosleh Wassim,Sharma Abhinav,Sidhu Mandeep S.,Page Brian,Sharma Umesh C.,Farkouh Michael E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s10557-017-6729-y/fulltext.html

Reference64 articles.

1. Nowbar AN, Howard JP, Finegold JA, Asaria P, Francis DP. 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: statistics from World Health Organisation and United Nations. Int J Cardiol. 2014;174(2):293–8.

2. National diabetes statistics report. 2014. www.cdc.gov/diabetes . Accessed Feb 6th, 2016.

3. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.

4. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.

5. Group BDS, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of point-of-care platforms for diabetes: (2) medications and devices;Sensors and Actuators Reports;2023-06

2. Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease–2;American Heart Journal;2023-02

3. Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review;Diabetes Therapy;2022-06-15

4. Life-threatening complications for diabetic patients taking SGLT2 inhibitors when undergoing surgery: A poorly recognised problem?;Journal of Perioperative Practice;2022-03-15

5. A Microtube-Based Wearable Closed-Loop Minisystem for Diabetes Management;Research;2022-01